Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.
Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.